These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9796962)

  • 21. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
    Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apoptosis loss and bcl-2 expression: key determinants of lymph node metastases in T1 breast cancer.
    Sierra A; Castellsagué X; Tórtola S; Escobedo A; Lloveras B; Peinado MA; Moreno A; Fabra A
    Clin Cancer Res; 1996 Nov; 2(11):1887-94. PubMed ID: 9816145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
    Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer.
    Chen X; Wu J; Lu H; Huang O; Shen K
    Cancer Sci; 2012 Feb; 103(2):262-8. PubMed ID: 22035021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression.
    Poelman SM; Adeyanju MO; Robertson MA; Recant WM; Karrison T; Fleming GF; Olopade OI; Conzen SD
    Clin Cancer Res; 2000 Oct; 6(10):4043-8. PubMed ID: 11051254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer.
    Borner MM; Brousset P; Pfanner-Meyer B; Bacchi M; Vonlanthen S; Hotz MA; Altermatt HJ; Schlaifer D; Reed JC; Betticher DC
    Br J Cancer; 1999 Feb; 79(5-6):952-8. PubMed ID: 10070896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.
    Faneyte IF; Schrama JG; Peterse JL; Remijnse PL; Rodenhuis S; van de Vijver MJ
    Br J Cancer; 2003 Feb; 88(3):406-12. PubMed ID: 12569384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
    Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
    Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
    Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
    Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer.
    Neri A; Marrelli D; Roviello F; DeMarco G; Mariani F; DeStefano A; Megha T; Caruso S; Corso G; Cioppa T; Pinto E
    Breast Cancer Res Treat; 2006 Sep; 99(1):77-83. PubMed ID: 16541314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities.
    Sarbia M; Stahl M; Fink U; Willers R; Seeber S; Gabbert HE
    Clin Cancer Res; 1998 Dec; 4(12):2991-7. PubMed ID: 9865911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation.
    Trask DK; Wolf GT; Bradford CR; Fisher SG; Devaney K; Johnson M; Singleton T; Wicha M
    Laryngoscope; 2002 Apr; 112(4):638-44. PubMed ID: 12150516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
    Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
    Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma.
    Allal AS; Waelchli L; Bründler MA
    Clin Cancer Res; 2003 Dec; 9(17):6489-96. PubMed ID: 14695153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.